Literature DB >> 24553530

Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit.

Tazo Stowe Inui1, Ralitza Parina, David C Chang, Thomas S Inui, Raul Coimbra.   

Abstract

BACKGROUND: Elderly patients with atrial fibrillation or flutter who experience ground-level falls are at risk for lethal head injuries. Patients on oral anticoagulation (OAC) for thromboprophylaxis may be at higher risk for these head injuries. Trauma surgeons treating these patients face a difficult choice: (1) continue OAC to minimize stroke risk while increasing the risk of a lethal head injury or (2) discontinue OAC to avoid intracranial hemorrhage while increasing the risk of stroke. To inform this choice, we conducted a retrospective cohort study to assess long-term outcomes and risk factors for mortality after presentation with a ground-level fall among patients with and without OAC.
METHODS: Retrospective analysis of the longitudinal version of the California Office of Statewide Planning and Development database was performed for years 1995 to 2009. Elderly anticoagulated patients (age > 65 years) with known atrial fibrillation or flutter who fell were stratified by CHA2DS2-VASc score and compared with a nonanticoagulated control cohort. Multivariable logistic regression including patient demographics, stroke risk, injury severity, and hospital type identified risk factors for mortality.
RESULTS: A total of 377,873 patient records met the inclusion criteria, 42,913 on OAC and 334,960 controls. The mean age was 82.4 and 80.6 years, respectively. Most were female, with CHA2DS2-VASc scores between 3 and 5. Mortality among OAC patients after a first fall was 6%, compared with 3.1% among non-OAC patients. Patients dying with a head injury constituted 31.6% of deaths within OAC patients compared with 23.8% among controls. Risk of eventual death with head injury exceeded annualized stroke risk for patients with CHA2DS2-VASc scores of 0 to 2. Predictors for mortality with head injury on the first admission included male sex, Asian ethnicity, a history of stroke, and trauma center admission.
CONCLUSION: Elderly patients on OAC for atrial fibrillation and/or flutter who fall have a greater risk for mortality compared with controls. Patients with low CHA2DS2-VASc scores (0-3) at high risk for falls with identified risk factors should speak to their prescribing physicians regarding the risk/benefits of continued use of OAC. LEVEL OF EVIDENCE: Epidemiologic/prognostic study, level III.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553530     DOI: 10.1097/TA.0000000000000138

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  17 in total

1.  [Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation].

Authors:  M Gosch; B Iglseder; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2016-07       Impact factor: 1.281

2.  Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents.

Authors:  Joe Yoshizawa; Jun Namiki; Yusho Nishida; Yasushi Kaneko; Shingo Hori
Journal:  Acute Med Surg       Date:  2016-04-26

3.  Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke.

Authors:  Emer R McGrath; Alan S Go; Yuchiao Chang; Leila H Borowsky; Margaret C Fang; Kristi Reynolds; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2016-12-30       Impact factor: 5.562

4.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

Review 5.  Direct Oral Anticoagulants in Emergency Trauma Admissions.

Authors:  Marc Maegele; Oliver Grottke; Herbert Schöchl; Oliver A Sakowitz; Michael Spannagl; Jürgen Koscielny
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594

6.  The epidemic of pre-injury oral antiplatelet and anticoagulant use.

Authors:  A E Berndtson; R Coimbra
Journal:  Eur J Trauma Emerg Surg       Date:  2014-05-01       Impact factor: 3.693

7.  Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation.

Authors:  Sudha Jayaraman; Jonathan H DeAntonio; Stefan W Leichtle; Jinfeng Han; Loren Liebrecht; Daniel Contaifer; Caroline Young; Christopher Chou; Julia Staschen; David Doan; Naren Gajenthra Kumar; Luke Wolfe; Tammy Nguyen; Gregory Chenault; Rahul J Anand; Jonathan D Bennett; Paula Ferrada; Stephanie Goldberg; Levi D Procter; Edgar B Rodas; Alan P Rossi; James F Whelan; Ventaka Ramana Feeser; Michael J Vitto; Beth Broering; Sarah Hobgood; Martin Mangino; Michel Aboutanos; Lorin Bachmann; Dayanjan S Wijesinghe
Journal:  J Trauma Acute Care Surg       Date:  2020-04       Impact factor: 3.697

8.  Ground-level falls among nonagenarians: the impact of pre-injury antithrombotic therapy.

Authors:  Jacques Bouget; Alexia Jouhanny; Louis Soulat; Emmanuel Oger
Journal:  Intern Emerg Med       Date:  2022-02-03       Impact factor: 5.472

9.  Unintentional fall-related mortality in the elderly: comparing patterns in two countries with different demographic structure.

Authors:  Marek Majdan; Walter Mauritz
Journal:  BMJ Open       Date:  2015-08-12       Impact factor: 2.692

10.  Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study.

Authors:  Stephen P Juraschek; Natalie Daya; Lawrence J Appel; Edgar R Miller; Kunihiro Matsushita; Erin D Michos; B Gwen Windham; Christie M Ballantyne; Elizabeth Selvin
Journal:  J Am Geriatr Soc       Date:  2019-07-10       Impact factor: 7.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.